CHLORPHENAMINE

The route of administration for chlorphenamine tablets is oral. Adults and the elderly 4 mg every 4-6 hours (maximum of 24mg daily). Children 6 - 12 years: 2mg every 4-6 hours (maximum of 12mg daily). Not recommended for use in children under 6 years of age.

Specific estimation of the frequency of adverse events for OTC products is inherently difficult (particularly numerator data). Adverse reactions which have been observed in clinical trials and which are considered to be common (occurring in ≥1% to <10% of subjects) or very common (occurring in ≥10% of subjects) are listed below by MedDRA System Organ Class.

The frequency of other adverse reactions identified during post-marketing use is unknown. g. increased energy, restlessness, nervousness). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard.

In common with other drugs having anticholinergic effects, chlorphenamine should be used with caution in conditions such as epilepsy, raised intra-ocular pressure including glaucoma, prostatic hypertrophy, severe hypertension or cardiovascular disease, bronchitis, bronchiectasis or asthma, hepatic impairment, renal impairment.

g increased energy, restlessness, nervousness). The anticholinergic properties of chlorphenamine may cause drowsiness, dizziness, blurred vision and psychomotor impairment in some patients which may seriously affect ability to drive and use machinery.

The effects of alcohol may be increased and therefore concurrent use should be avoided. Should not be used with other antihistamine containing products, including antihistamine containing cough and cold medicines. Excipients Contains lactose.

Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicine. Keep out of the sight and reach of children.

The tablets are contraindicated in patients who are hypersensitive to antihistamines or any of the other tablet ingredients. The anticholinergic properties of chlorphenamine are intensified by monoamine oxidase inhibitors (MAOIs). Chlorphenamine is therefore contraindicated in patients who have been treated with MAOIs within the last fourteen days.